Cite
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.
MLA
Anforth, R. M., et al. “Cutaneous Manifestations of Dabrafenib (GSK2118436): A Selective Inhibitor of Mutant BRAF in Patients with Metastatic Melanoma.” British Journal of Dermatology, vol. 167, no. 5, Nov. 2012, pp. 1153–60. EBSCOhost, https://doi.org/10.1111/j.1365-2133.2012.11155.x.
APA
Anforth, R. M., Blumetti, T. C. M. P., Kefford, R. F., Sharma, R., Scolyer, R. A., Kossard, S., Long, G. V., & Fernandez-Peñas, P. (2012). Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. British Journal of Dermatology, 167(5), 1153–1160. https://doi.org/10.1111/j.1365-2133.2012.11155.x
Chicago
Anforth, R.M., T.C.M.P. Blumetti, R.F. Kefford, R. Sharma, R.A. Scolyer, S. Kossard, G.V. Long, and P. Fernandez-Peñas. 2012. “Cutaneous Manifestations of Dabrafenib (GSK2118436): A Selective Inhibitor of Mutant BRAF in Patients with Metastatic Melanoma.” British Journal of Dermatology 167 (5): 1153–60. doi:10.1111/j.1365-2133.2012.11155.x.